Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04019717 | Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection | PHASE2 | COMPLETED | 10 | — | — | Jun 20, 2019 | Mar 23, 2020 | May 4, 2020 | 3 | Belgium, Mauritius +1 |
SVR defined as the HCV RNA \< lower limit of quantitation (LLOQ) at 12 weeks after end of treatment
| Arm | Type | Description |
|---|---|---|
| 8 weeks | EXPERIMENTAL | - |
| 12 weeks | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AT-527 | DRUG | Nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase |
| Daclatasvir | DRUG | Inhibitor of HCV nonstructural protein 5A (NS5A) |
Inclusion Criteria: * Body mass index (BMI) of 18-35 kg/m2 * Must agree to use protocol-specified methods of contraception * Negative pregnancy test * HCV genotype 1 * Documented history compatible with chronic hepatitis C * HCV RNA ≥ 10,000 IU/mL at Screening. * Willing to comply with the study re...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | — | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | — | Undisclosed |